AAAAAA

   
Results: 1-9 |
Results: 9
Separation methods for anthraquinone related anti-cancer drugs
Authors: Loadman, PM Calabrese, CR
Citation: Pm. Loadman et Cr. Calabrese, Separation methods for anthraquinone related anti-cancer drugs, J CHROMAT B, 764(1-2), 2001, pp. 193-206
A preclinical pharmacokinetic study of the bioreductive drug AQ4N
Authors: Loadman, PM Swaine, DJ Bibby, MC Welham, KJ Patterson, LH
Citation: Pm. Loadman et al., A preclinical pharmacokinetic study of the bioreductive drug AQ4N, DRUG META D, 29(4), 2001, pp. 422-426
High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide
Authors: Swaine, DJ Loadman, PM Bibby, MC Graham, MA Patterson, LH
Citation: Dj. Swaine et al., High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide, J CHROMAT B, 742(2), 2000, pp. 239-245
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
Authors: Grosios, K Loadman, PM Swaine, DJ Pettit, GR Bibby, MC
Citation: K. Grosios et al., Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma, ANTICANC R, 20(1A), 2000, pp. 229-233
Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development
Authors: Phillips, RM Burger, AM Loadman, PM Jarrett, CM Swaine, DJ Fiebig, HH
Citation: Rm. Phillips et al., Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: Implications for enzyme-directed bioreductive drug development, CANCER RES, 60(22), 2000, pp. 6384-6390
Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice
Authors: Loadman, PM Phillips, RM Lim, LE Bibby, MC
Citation: Pm. Loadman et al., Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice, BIOCH PHARM, 59(7), 2000, pp. 831-837
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor modelswith differing responses to PK1
Authors: Loadman, PM Bibby, MC Double, JA Al-Shakhaa, WM Duncan, R
Citation: Pm. Loadman et al., Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor modelswith differing responses to PK1, CLIN CANC R, 5(11), 1999, pp. 3682-3688
In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans
Authors: Calabrese, CR Loadman, PM Lim, LSE Bibby, MC Double, JA Brown, JE Lamb, JH
Citation: Cr. Calabrese et al., In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans, DRUG META D, 27(2), 1999, pp. 240-245
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs
Authors: Phillips, RM Pearce, J Loadman, PM Bibby, MC Cooper, PA Swaine, DJ Double, JA
Citation: Rm. Phillips et al., Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs, CANCER RES, 58(23), 1998, pp. 5263-5266
Risultati: 1-9 |